Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We recently demonstrated that heat shock protein 90 (HSP90) is involved in the regulation of runt-related transcription factor 2 via the AKT/GSK-3β/β-catenin signaling pathway in OS.
|
31595984 |
2020 |
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Using next-generation RNA-sequencing, protein-based assays, as well as the loss- and gain-of-function approaches in selected osteosarcoma cell lines, we show that osteopontin messenger RNA levels closely correlate with RUNX2 expression and that RUNX2 controls the levels of secreted osteopontin.
|
30637720 |
2019 |
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
LncRNA TUG1 promotes the development of osteosarcoma through RUNX2.
|
31555384 |
2019 |
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Materials and methods:</b> The levels of 3,4-dihydroxyphenylacetic acid, norepinephrine, serotonin, and 5-hydroxyindoleacetic acid in cancer tissue and in adjacent and non-oncological bone tissue were analysed by high-performance liquid chromatography, and the gene expression of catecholamine receptors and of dopamine β-hydroxylase, monoaminoxidase, ki67, and Runx2 in the osteosarcoma tissue, tissue adjacent to the tumour, non-oncological bone, and human brain tissue was analysed by RT-PCR.
|
31291139 |
2019 |
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
NNT-As1 functions as a cancer-promoting lncRNA by downregulating miR-320a, thus increasing the protein expression level of beta-catenin, RUNX2 and IGF-1R as well as activation of Akt in osteosarcoma.
|
30489194 |
2019 |
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, fluorescence in situ hybridization was used to assess copy number status for RUNX2, a known transcriptional regulator of osteoblastic differentiation which has previously been reported to be dysregulated in osteosarcomas.
|
31669178 |
2019 |
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Recently, aberrant expression of Runx2 has been found in OS, thereby contributing to the development, and progression of OS.
|
28681940 |
2018 |
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Intriguingly, runt-related transcription factor 2 (RUNX2) is expressed at higher level in numerous human cancers such as pancreatic cancer and osteosarcoma, indicating that, in addition to its pro-osteogenic role, RUNX2 has a pro-oncogenic potential.
|
29558908 |
2018 |
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, our data reveals that lncRNA SNHG20/miR-139/RUNX2 axis modulates the osteosarcoma tumorigenesis and apoptosis via mitochondrial apoptosis pathway, providing a novel insight for the pathophysiological process.
|
30072099 |
2018 |
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of the ectodomain-releasing protease ADAM17 is directly regulated by the osteosarcoma and bone-related transcription factor RUNX2.
|
29923217 |
2018 |
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, we revealed that silybin inhibited OS cell viability by altering the protein levels of β-catenin and Runt-related transcription factor 2 (RUNX2) as determined by western blot and immunocytochemistry (ICC).
|
29068478 |
2018 |
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our results indicate that miR-302b functions as a tumour repressor in the invasion and migration of osteosarcoma by directly downregulating Runx2 expression and may be a potential therapeutic target for osteosarcoma.
|
29042587 |
2017 |
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We analyzed protein levels and nuclear localization of β-catenin and RUNX2 in a panel of human osteosarcoma cell lines (SAOS, MG63, U2OS, HOS, G292, and 143B).
|
28370561 |
2017 |
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Vitamin D Impacts the Expression of Runx2 Target Genes and Modulates Inflammation, Oxidative Stress and Membrane Vesicle Biogenesis Gene Networks in 143B Osteosarcoma Cells.
|
28300755 |
2017 |
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the RUNX2 binding site, which encompasses positions ‑496 to ‑501 bp, was required to achieve maximal IPO8 promoter activity in Saos‑2 human osteosarcoma cells.
|
27277970 |
2016 |
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, we suggest that the miR-205/RUNX2 axis may serve as a potential target for the treatment of OS.
|
27035764 |
2016 |
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
We also identified that RUNX2 is a direct target of bromodomain-containing protein 4 (BRD4) inhibition by JQ1 in OS cells.
|
25307878 |
2015 |
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Runx2, a critical transcription factor in bone development, is frequently amplified and overexpressed in OS.
|
26528706 |
2015 |
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of RUNX2 protected JQ1-sensitive OS cells from the effect of JQ1, and siRNA-mediated inhibition of RUNX2 sensitized the same cells to JQ1.
|
25307878 |
2015 |
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Based on this knowledge, we found more genes related to the pathogenesis of osteosarcoma and these genes could exert similar function as Runx2, a risk factor confirmed in osteosarcoma, this study may help better understand the genetic mechanism and provide new molecular markers and therapies for osteosarcoma.
|
24293382 |
2014 |
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle.
|
24646477 |
2014 |
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A loss-of-function approach was used to investigate the effects of small hairpin RNA-mediated knockdown of YAP1 on the expression of RUNX2, CyclinD1, and matrix metalloproteinase-9 (MMP-9) as well as the proliferative activities and invasive potential in OS MG-63 cells (evaluated by MTT and Transwell assays, respectively).
|
23527718 |
2013 |
Osteosarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Analysis of previously published OS aCGH data (GSE9654) and aCGH data from this study (GSE19180) identified significant deletion of WWOX in 30% (6/20) of OS samples, whilst significant increase in both RUNX2 and VEGFA gene copy numbers were detected in 55% (11/20) and 60% (12/20) of OS samples, respectively.
|
24330824 |
2013 |
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thus, regulatory mechanisms controlling Runx2 expression in osteosarcoma cells must balance Runx2 protein levels to promote its putative oncogenic functions, while avoiding suppression of bone tumor growth.
|
22949168 |
2013 |
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The p53-dependent miR-34c is the most significantly down-regulated RUNX2 targeting microRNAs in OS.
|
23720736 |
2013 |